DEF 14A: HilleVax, Inc. Announces 2024 Annual Meeting of Stockholders

HilleVax, Inc. will hold its annual meeting of stockholders virtually on June 6, 2024, to elect directors, ratify the appointment of Ernst & Young LLP, and approve an amendment to the company's certificate of incorporation.

Summary

• HilleVax, Inc. is holding its annual meeting of stockholders on June 6, 2024, at 12:00 p.m. Eastern Time, as a virtual meeting.
• Stockholders of record as of April 11, 2024, are entitled to vote.
• The meeting will address the election of three Class II directors for a three-year term expiring in 2027, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to the company's certificate of incorporation to permit exculpation of certain officers.
• The board of directors recommends voting for the election of Gary Dubin, Patrick Heron, and Jaime Sepulveda as directors, for the ratification of Ernst & Young LLP, and for the approval of the amendment to the certificate of incorporation.
• Stockholders can vote via the Internet, telephone, or mail, or virtually during the annual meeting after registering at www.proxydocs.com/HLVX by 5:00 p.m. Eastern Time on June 5, 2024.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the board's recommendations and efforts to facilitate stockholder participation.

Positives

• The company is taking advantage of SEC rules to furnish proxy materials online, reducing costs and environmental impact.
• The virtual meeting format is designed for ease of stockholder access and participation.
• The board of directors is recommending qualified candidates for election as directors.
• The audit committee has pre-approved all audit and permissible non-audit services provided by Ernst & Young LLP.
• The proposed amendment to the certificate of incorporation aims to attract and retain qualified officers.

Risks

• Failure to ratify the selection of Ernst & Young LLP would require the audit committee to reconsider its choice of accounting firm.
• The proposed amendment to exculpate officers does not eliminate liability for breaches of the duty of loyalty, acts or omissions not in good faith, or transactions where the officer derived an improper personal benefit.
• If stockholders do not approve the Officer Exculpation Charter Amendment, the company may be at a disadvantage in attracting and retaining exceptional officer candidates.

Future Outlook

The company intends to file a proxy statement and WHITE proxy card with the SEC in connection with its solicitation of proxies for the 2025 annual meeting.

Management Comments

• Robert Hershberg, M.D., Ph.D., Chairman, President and Chief Executive Officer, expressed appreciation for stockholders' continued support and interest in HilleVax, Inc.

Industry Context

The proposal to amend the certificate of incorporation to permit exculpation of certain officers reflects a trend among Delaware companies following the 2022 amendment to the Delaware General Corporation Law, aiming to attract and retain qualified officers in a competitive market.

Comparison to Industry Standards

• The director compensation program, including annual retainers and equity awards, is generally consistent with compensation practices at similarly sized biopharmaceutical companies.
• The indemnification agreements with directors and executive officers are standard practice to attract and retain qualified individuals, aligning with Delaware law and industry norms.
• The company's prohibition against pledging and hedging of company stock by officers, directors, and employees is a common practice to prevent insider trading and maintain investor confidence.

Corporate Governance

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, including the election of directors and changes to corporate governance.
• Officers and directors may be impacted by the proposed amendment to the certificate of incorporation regarding exculpation.
• Employees are indirectly impacted through the company's overall governance and compensation policies.

Next Steps

• Stockholders are urged to vote on the proposals before the annual meeting.
• The company will file the Officer Exculpation Charter Amendment with the Delaware Secretary of State if approved by stockholders.
• The company will announce preliminary voting results at the annual meeting and file a Form 8-K with final results.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Ernst & Young, Officer Exculpation, Stockholders, Corporate Governance, HilleVax